Vericel's NexoBrid gets FDA approval for pediatric severe burn treatment

Vericel Corp

FDA approved NexoBrid for eschar removal in pediatric patients with deep partial- and full-thickness thermal burns.
Approval based on Phase 3 CIDS trial and additional pediatric data from earlier studies.
Target customer base expands to approximately 20 pediatric burn centers in the U.S.
NexoBrid was previously approved for adults in December 2022; pediatric indication adds new revenue opportunity.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.